W. Todd Kays, PhD

W. Todd Kays, PhD has an extensive work experience in the pharmaceutical industry. W. Todd currently holds the position of Vice President of Dermatology at Vial starting from December 2022. Prior to this, they worked as a Principal at Clinical Development Consulting Services in April 2020.

From November 2020 to July 2022, Todd Kays served as the Vice President of Clinical Development at Verrica Pharmaceuticals. Before that, they held senior positions at Glenmark Pharmaceuticals, including Senior Vice President and Head of Global Clinical Operations from October 2017 to April 2020, and Vice President of Global Clinical Development - Generics from February 2017 to September 2017.

In their earlier career, Todd Kays held various leadership roles at Teva Pharmaceuticals as the Vice President of Biopharmaceutics from 2014 to 2016, and at Amneal Pharmaceuticals as the Vice President of Clinical Regulatory Affairs from 2011 to 2014. W. Todd also worked as the Vice President of Clinical Research at PharmaNet Development Group, Inc. in 2010, and as the Vice President of Strategic Development at Symbio, LLC from 2006 to 2010.

Prior to that, they held important positions at ABD Pharmaceuticals as the Vice President of Scientific Affairs and CSO from 2005 to 2006, and at Clay-Park Labs, Inc./Agis Industries as the Vice President of Clinical Affairs from 2002 to 2005.

Throughout their career, Todd Kays has gained expertise in clinical development, regulatory affairs, and strategic development, contributing to the growth and success of multiple pharmaceutical companies.

Dr. W. Todd Kays holds a Ph.D. in Anatomy and Cell Biology from the University of Virginia School of Medicine. W. Todd completed their Master of Science degree in Physiology from Louisiana State University in 1986. Prior to that, they obtained a Bachelor of Arts degree in Biology from the University of Richmond. In January 2023, Dr. Kays obtained a certification in GCP for Clinical Trials with Investigational Drugs and Biologics, from the CITI Program.